Trinity Biotech Announces Clinical Study Results Showing Next-Gen CGM+ Wearable Biosensor Platform Delivers Purpose-Built Capability To Iden
Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates practical value of Trinity Biotech's proprietary multi-sensor wearable biosensor technology beyond glucose